27 Jun 2014 16:16
27 June 2014
Silence Therapeutics plc
Result of General Meeting
Silence Therapeutics plc, AIM: SLN ('Silence'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.
Enquiries:
Silence Therapeutics plc | +44 (0)20 3700 9711 |
Timothy Freeborn, Finance Director & Company Secretary | |
Rozi Morris, Communications Manager | |
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor |
About Silence Therapeutics plc (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNAi (RNA interference) therapeutics platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.
Listed on London's AIM since 2006, Silence is one of only six quoted companies globally with well-validated RNA delivery technology. It has a robust IP estate, with three Phase II trials already completed (pending results).